Term
|
Definition
recombinant tissue plasminogen activator (rt - PA) causes fibrinolysis by binding to fibrin in a thrombus (clot) and converts entrapped plasminogen to plasmin |
|
|
Term
|
Definition
|
|
Term
Name an obvious contraindication and side effect of atleplase |
|
Definition
CI: bleeding
SE: major bleeding (e.g. ICH)
|
|
|
Term
Name antihypertensives used in stroke |
|
Definition
|
|
Term
Why would anti-hypertensives be used in stroke? |
|
Definition
used to decrease BP and possibly qualify patients for rt-PA; decrease BP gradually |
|
|
Term
|
Definition
Statement. Not a question. |
|
|
Term
Acute management of subarachinoid hemorrhage |
|
Definition
(a) SAH is associated with a high incidence of delayed cerebral ischemia 2 weeks following the stroke
(b) Vasospasm is thought to be the cause of the delayed ischemia and occurs 4 - 21 days after the bleed
(c) Nimodipine (Nimotop) 60 mg PO Q4h should be initiated and continued for 21 days
(d) Watch BP |
|
|
Term
|
Definition
Control blood pressure and lipids
Ensure optimal blood glucose control in diabetes
Use anticoagulants for A-fib
Encourage life changes: stop smoking, increase physical exercise, improve diet, encourage weight reduction (BMI < 25) and limit alcohol intake (LOL, yea right!) |
|
|
Term
Name secondary prevention for stroke? |
|
Definition
Previous TIA or stroke; non-cardioembolic. If previous cardioembolic stroke, use warfarin. |
|
|
Term
Name agents used in antiplatelet therapy |
|
Definition
Aspirin
Clopidogrel
Dipryidamole ER/ Aspirin
|
|
|
Term
brand name for Clopidogrel |
|
Definition
|
|
Term
Brand name for Dipyridamole ER/ Asprin |
|
Definition
|
|
Term
|
Definition
Statement. Not a question. |
|
|
Term
Drug interactions of note (I got lazy):
(a) avoid use, if possible, with other agents that increase bleeding risk, including other antiplatelets (although clopidogrel is generally used with low - dose aspirin), NSAIDs, anticoagulants, ginko, etc.
(b) Clopidogrel is a prodrug metabolized by CYP 2C19. Avoid concomitant use with strong or moderate 2C19 inhibitors (omeprazole, esomeprazole, cimetidine, fluconazole, ketoconazole, voriconazole, fluoxetine, fluvoxamine) |
|
Definition
Statement. Not a question. |
|
|